Patient Square Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Patient Square Capital’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.7M	Sell	370,000 -30,645	-8%	-$714K	1.5%	19
2026 Q1	$9.44M	Buy	400,645 +190,645	+91%	+$4.87M	1.67%	17
2025 Q4	$6.1M	Buy	+210,000	New	+$5.38M	1.31%	18

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Patient Square Capital's ARQT Position: Q2 2026 in Review

Patient Square Capital reduced its Arcutis Biotherapeutics (ARQT) stake by 7.6% in Q2 2026, selling an estimated $714K and leaving 370,000 shares worth $9.7M. The position accounts for 1.5% of the portfolio, ranked #19.

Patient Square Capital first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Patient Square Capital held 370,000 shares of Arcutis Biotherapeutics worth $9.7M as of Q2 2026.
Patient Square Capital sold 30,645 Arcutis Biotherapeutics shares in Q2 2026, an estimated $714K.
Arcutis Biotherapeutics made up 1.5% of Patient Square Capital's portfolio in Q2 2026, its #19 holding.
Patient Square Capital first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.